1. Home
  2. OSS vs BCYC Comparison

OSS vs BCYC Comparison

Compare OSS & BCYC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

OSS

One Stop Systems Inc.

N/A

Current Price

$9.07

Market Cap

248.7M

Sector

Technology

ML Signal

N/A

Logo Bicycle Therapeutics plc

BCYC

Bicycle Therapeutics plc

N/A

Current Price

$3.68

Market Cap

291.8M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
OSS
BCYC
Founded
1998
2009
Country
United States
United Kingdom
Employees
N/A
N/A
Industry
Computer Manufacturing
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
248.7M
291.8M
IPO Year
2017
2019

Fundamental Metrics

Financial Performance
Metric
OSS
BCYC
Price
$9.07
$3.68
Analyst Decision
Strong Buy
Buy
Analyst Count
2
10
Target Price
$10.00
$13.90
AVG Volume (30 Days)
660.7K
357.7K
Earning Date
05-06-2026
04-30-2026
Dividend Yield
N/A
N/A
EPS Growth
133.85
N/A
EPS
N/A
N/A
Revenue
$37,027,382.00
N/A
Revenue This Year
$22.19
N/A
Revenue Next Year
$20.67
N/A
P/E Ratio
N/A
N/A
Revenue Growth
34.46
N/A
52 Week Low
$4.17
$3.75
52 Week High
$20.88
$9.16

Technical Indicators

Market Signals
Indicator
OSS
BCYC
Relative Strength Index (RSI) 30.27 34.94
Support Level $8.56 N/A
Resistance Level $14.36 $4.51
Average True Range (ATR) 0.45 0.18
MACD -0.08 -0.06
Stochastic Oscillator 7.71 6.13

Price Performance

Historical Comparison
OSS
BCYC

About OSS One Stop Systems Inc.

One Stop Systems Inc designs, manufactures, and markets specialized rugged high-performance compute ("HPC"), high-speed switch fabrics, and storage systems, which are designed to target edge applications for artificial intelligence ("AI") / machine learning ("ML"), sensor processing, sensor fusion, and autonomy.

About BCYC Bicycle Therapeutics plc

Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United Kingdom.

Share on Social Networks: